Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adult patients with de novo acute myeloid leukemia show a functional deregulation of redox balance at diagnosis which is correlated with molecular subtypes and overall survival.
Mondet J, Presti CL, Garrel C, Skaare K, Mariette C, Carras S, Park S, Carré M, Bulabois CE, Molina L, Gressin R, Thiebaut A, Courby S, Socoro-Yuste N, Faure P, Leer-Florin AM, Cahn JY, Mossuz P. Mondet J, et al. Among authors: gressin r. Haematologica. 2019 Sep;104(9):e393-e397. doi: 10.3324/haematol.2018.206821. Epub 2019 Feb 28. Haematologica. 2019. PMID: 30819920 Free PMC article. No abstract available.
The Negative Influence of Baseline Cell-free DNA on Long-term Survival in DLBCL Depends on Frontline Treatment Intensity.
Desmots F, Rossille D, Roussel M, Pangault C, Louarn L, De Saint Jore M, Le Gouill S, Bouabdallah K, Delwail V, Gressin R, Cornillon J, Damaj G, Maisonneuve H, Damotte D, Kraeber-Bodere F, Lamy T, Parrens MC, Milpied N, Fest T. Desmots F, et al. Among authors: gressin r. Clin Cancer Res. 2023 Jun 13;29(12):2280-2290. doi: 10.1158/1078-0432.CCR-22-2964. Clin Cancer Res. 2023. PMID: 37014666 Free article. Clinical Trial.
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G, Okamoto R, Nakahara S, Hu P, Appiani C, Nemat S, Cavalli F; LYM-3002 investigators. Robak T, et al. Lancet Oncol. 2018 Nov;19(11):1449-1458. doi: 10.1016/S1470-2045(18)30685-5. Epub 2018 Oct 19. Lancet Oncol. 2018. PMID: 30348538 Clinical Trial.
Systemic relapses of primary CNS lymphomas (PCNSL): a LOC network study.
Dufour J, Choquet S, Hoang-Xuan K, Schmitt A, Ahle G, Houot R, Taillandier L, Gressin R, Casasnovas O, Marolleau JP, Tamburini J, Serrier C, Perez E, Paillassa J, Gyan E, Chauchet A, Ursu R, Kas A, Soussain C, Houillier C. Dufour J, et al. Among authors: gressin r. Ann Hematol. 2023 May;102(5):1159-1169. doi: 10.1007/s00277-023-05108-6. Epub 2023 Mar 29. Ann Hematol. 2023. PMID: 36991231
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.
Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov E, Alexeeva J, Pereira J, Drach J, Mayer J, Hong X, Okamoto R, Pei L, Rooney B, van de Velde H, Cavalli F; LYM-3002 Investigators. Robak T, et al. N Engl J Med. 2015 Mar 5;372(10):944-53. doi: 10.1056/NEJMoa1412096. N Engl J Med. 2015. PMID: 25738670 Free article. Clinical Trial.
Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study.
Sarkozy C, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Damaj G, Gastinne T, Tessoulin B, Ribrag V, Casasnovas O, Haioun C, Houot R, Jardin F, Van Den Neste E, Cheminant M, Morschhauser F, Callanan M, Safar V, Gressin R, Hermine O, Le Gouill S. Sarkozy C, et al. Among authors: gressin r. J Clin Oncol. 2024 Mar 1;42(7):769-773. doi: 10.1200/JCO.23.01586. Epub 2023 Dec 18. J Clin Oncol. 2024. PMID: 38109684
A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma.
Gressin R, Daguindau N, Tempescul A, Moreau A, Carras S, Tchernonog E, Schmitt A, Houot R, Dartigeas C, Pignon JM, Corm S, Banos A, Mounier C, Dupuis J, Macro M, Fleury J, Jardin F, Sarkozy C, Damaj G, Feugier P, Fornecker LM, Chabrot C, Dorvaux V, Bouadallah K, Amorin S, Garidi R, Voillat L, Joly B, Celigny PS, Morineau N, Moles MP, Zerazhi H, Fontan J, Arkam Y, Alexis M, Delwail V, Vilque JP, Ysebaert L, Le Gouill S, Callanan MB; Lymphoma Study Association. Gressin R, et al. Haematologica. 2019 Jan;104(1):138-146. doi: 10.3324/haematol.2018.191429. Epub 2018 Aug 31. Haematologica. 2019. PMID: 30171024 Free PMC article. Clinical Trial.
Extranucleolar CYCLON Staining Pattern Is Strongly Associated to Relapse/Refractory Disease in R-CHOP-treated DLBCL.
Bouroumeau A, Bussot L, Sartelet H, Fournier C, Betton-Fraisse P, Col E, David-Boudet L, McLeer A, Lefebvre C, Raskovalova T, Jacob MC, Vettier C, Chevalier S, Algrin C, Carras S, Gressin R, Callanan MB, Bonnefoix T, Emadali A. Bouroumeau A, et al. Among authors: gressin r. Hemasphere. 2021 Jun 12;5(7):e598. doi: 10.1097/HS9.0000000000000598. eCollection 2021 Jul. Hemasphere. 2021. PMID: 34131636 Free PMC article. No abstract available.
Adverse outcome in follicular lymphoma is associated with MYC rearrangements but not MYC extra copies.
Bussot L, Chevalier S, Cristante J, Grange B, Tesson B, Deteix-Santana C, Orsini-Piocelle F, Leyronnas C, Dupire S, Gressin R, Salles G, Bachy E, Emadali A, Valmary-Degano S, Huet S, Lefebvre C, Carras S. Bussot L, et al. Among authors: gressin r. Br J Haematol. 2021 Jul;194(2):382-392. doi: 10.1111/bjh.17550. Epub 2021 Jun 21. Br J Haematol. 2021. PMID: 34155628
132 results